use-cases · 1 min read
AI for Pharmaceuticals: From Literature Review to Pharmacovigilance
How pharma teams use Bhogar AI for literature review, regulatory submissions and pharmacovigilance - without compromising 21 CFR Part 11 compliance.
BABhogar AI TeamProduct & Engineering
Pharma teams sit on enormous unstructured corpora - clinical literature, trial protocols, adverse-event reports, regulatory submissions - and have strict compliance constraints on how AI can touch any of it.
Why it matters
The right architecture handles 21 CFR Part 11 audit trails, deterministic outputs where required, and per-document provenance. Bolt-on AI fails the first audit; designed-in AI sails through.
How Bhogar AI approaches it
Bhogar AI ships pharma-ready building blocks: validated KBs with provenance, deterministic-mode workflows, signed audit trails and BAAs/quality agreements available for enterprise plans.
- Literature-review agents with per-claim citations
- Pharmacovigilance triage workflows for adverse events
- Regulatory submission drafting with redline tracking
- 21 CFR Part 11 compatible audit trails
- Validated KBs with provenance and version control
What you get
Pharma customers deploy AI into regulated workflows that compliance signs off on the first time, instead of after months of remediation.